

World Journal of *Transplantation*

World J Transplant 2022 August 18; 12(8): 211-280



Contents

Monthly Volume 12 Number 8 August 18, 2022

REVIEW

- 211 Hypertension in kidney transplant recipients
Alexandrou ME, Ferro CJ, Boletis I, Papagianni A, Sarafidis P

MINIREVIEWS

- 223 Acute kidney injury and the compensation of kidney function after nephrectomy in living donation
Okumura K, Grace H, Sogawa H, Yamanaga S
- 231 Kidney disease in non-kidney solid organ transplantation
Swanson KJ

ORIGINAL ARTICLE

Retrospective Cohort Study

- 250 Emergency department visits and hospital admissions in kidney transplant recipients during the COVID-19 pandemic: A hospital-based study
Wongtanasarasasin W, Phinyo P

Retrospective Study

- 259 Trends and outcomes of liver transplantation among older recipients in the United States
Okumura K, Lee JS, Dhand A, Sogawa H, Veillette G, John D, Misawa R, Bodin R, Wolf DC, Diflo T, Nishida S

SYSTEMATIC REVIEWS

- 268 Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorder: A systematic review
Reiche W, Tauseef A, Sabri A, Mirza M, Cantu D, Silberstein P, Chandan S

ABOUT COVER

Editorial Board Member of *World Journal of Transplantation*, Luis Cesar Bredt, FRCS (Hon), MD, PhD, Professor, Surgical Oncologist, Abdominal and Hepatobiliary Surgery, Renascença Hospital, Aracaju 49010-020, Sergipe, Brazil. lcbredt@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Transplantation* (WJT, *World J Transplant*) is to provide scholars and readers from various fields of transplantation with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJT mainly publishes articles reporting research results obtained in the field of transplantation and covering a wide range of topics including bone transplantation, brain tissue transplantation, corneal transplantation, descemet stripping endothelial keratoplasty, fetal tissue transplantation, heart transplantation, kidney transplantation, liver transplantation, lung transplantation, pancreas transplantation, skin transplantation, etc.

INDEXING/ABSTRACTING

The WJT is now abstracted and indexed in PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yi-Xuan Cai; **Production Department Director:** Xu Guo; **Editorial Office Director:** Jia-Ping Yan.

NAME OF JOURNAL

World Journal of Transplantation

ISSN

ISSN 2220-3230 (online)

LAUNCH DATE

December 24, 2011

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Maurizio Salvadori, Sami Akbulut, Vassilios Papalois, Atul C Mehta

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2220-3230/editorialboard.htm>

PUBLICATION DATE

August 18, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/gerinfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/gerinfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/gerinfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Hypertension in kidney transplant recipients

Maria-Eleni Alexandrou, Charles J Ferro, Ioannis Boletis, Aikaterini Papagianni, Pantelis Sarafidis

Specialty type: Transplantation

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: He Z, China; Parajuli S, United States

Received: April 30, 2022

Peer-review started: April 30, 2022

First decision: May 31, 2022

Revised: June 7, 2022

Accepted: August 6, 2022

Article in press: August 6, 2022

Published online: August 18, 2022



Maria-Eleni Alexandrou, Aikaterini Papagianni, Pantelis Sarafidis, Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece

Charles J Ferro, Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2WB, United Kingdom

Ioannis Boletis, Department of Nephrology, Laiko General Hospital, National and Kapodistrian University, Athens 11527, Greece

Corresponding author: Pantelis Sarafidis, MD, MSc, PhD, Associate Professor, Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Konstantinoupolis 49, Thessaloniki 54642, Greece. psarafidis11@yahoo.gr

Abstract

Kidney transplantation is considered the treatment of choice for end-stage kidney disease patients. However, the residual cardiovascular risk remains significantly higher in kidney transplant recipients (KTRs) than in the general population. Hypertension is highly prevalent in KTRs and represents a major modifiable risk factor associated with adverse cardiovascular outcomes and reduced patient and graft survival. Proper definition of hypertension and recognition of special phenotypes and abnormal diurnal blood pressure (BP) patterns is crucial for adequate BP control. Misclassification by office BP is commonly encountered in these patients, and a high proportion of masked and uncontrolled hypertension, as well as of white-coat hypertension, has been revealed in these patients with the use of ambulatory BP monitoring. The pathophysiology of hypertension in KTRs is multifactorial, involving traditional risk factors, factors related to chronic kidney disease and factors related to the transplantation procedure. In the absence of evidence from large-scale randomized controlled trials in this population, BP targets for hypertension management in KTR have been extrapolated from chronic kidney disease populations. The most recent Kidney Disease Improving Global Outcomes 2021 guidelines recommend lowering BP to less than 130/80 mmHg using standardized BP office measurements. Dihydropyridine calcium channel blockers and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers have been established as the preferred first-line agents, on the basis of emphasis placed on their favorable outcomes on graft survival. The aim of this review is to provide previous and recent evidence on prevalence, accurate diagnosis, pathophysiology and treatment of hypertension in KTRs.

Key Words: Hypertension; Kidney transplantation; Epidemiology; Diagnosis; Physiopathology; Therapy

Core Tip: Kidney transplantation is considered the treatment of choice for end-stage kidney disease patients. However, the residual cardiovascular risk remains significantly higher in kidney transplant recipients than in the general population. This article summarizes available evidence on prevalence, abnormal blood pressure phenotypes and diurnal patterns as well as on the association of hypertension with target organ damage and clinical outcomes in kidney transplantation. The complex pathophysiology, treatment goals and recent data on therapeutic options for management of hypertension in kidney transplant recipients are also discussed.

Citation: Alexandrou ME, Ferro CJ, Boletis I, Papagianni A, Sarafidis P. Hypertension in kidney transplant recipients. *World J Transplant* 2022; 12(8): 211-222

URL: <https://www.wjgnet.com/2220-3230/full/v12/i8/211.htm>

DOI: <https://dx.doi.org/10.5500/wjt.v12.i8.211>

INTRODUCTION

Kidney transplantation is considered the optimal choice for renal replacement therapy in end-stage kidney disease due to improved survival and quality of life compared to dialysis modalities; this survival benefit has been attributed to kidney function improvement and delay of progression of cardiovascular disease[1]. Nevertheless, cardiovascular disease remains the leading cause of death in these patients in the early (< 10) post-transplant years[2]. Among traditional cardiovascular disease risk factors, hypertension represents the most prominent comorbidity post transplantation and a major cause of allograft dysfunction and adverse patient outcomes[3]. The diagnosis and treatment of hypertension in kidney transplantation has been traditionally based on office blood pressure (BP) measurements; BP control therefore remains suboptimal due to high rates of resistant and masked hypertension and abnormal diurnal BP patterns[4]. Controversies over BP targets and optimal antihypertensive regimen remain unresolved and should be further explored in well-designed randomized clinical trials (RCTs) in order to optimize hypertension management in this population.

EPIDEMIOLOGY OF HYPERTENSION IN KIDNEY TRANSPLANT RECIPIENTS

Prevalence of hypertension and abnormal BP phenotypes by the various metrics and definitions

The prevalence of hypertension is particularly high among kidney transplant recipients (KTRs) with previously reported rates between 70%-90%[5] and more recently even exceeding 95% of this population [6]. The source of variability in estimates of prevalence, control and different phenotypes of hypertension among KTRs is attributed to differences in the definitions used for hypertension diagnosis and in the type of BP measurement used (in office *vs* out-of-office setting) across various studies. Defining the diagnostic threshold for hypertension based on office and ambulatory BP measurements has been a matter of intense debate in chronic kidney disease (CKD) patients and more specifically in KTRs[7], with the two major existing hypertension guidelines producing confusion[8].

The cutoff values for hypertension diagnosis proposed by the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines for office and ambulatory BP monitoring (ABPM) measurements were $\geq 130/80$ mmHg and $\geq 125/75$ mmHg, respectively[9] (Table 1), while those proposed by the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines were office BP $\geq 140/90$ mmHg and ABPM $\geq 130/80$ mmHg[10]. In the more recent 2021 Kidney Disease Improving Global Outcomes BP guidelines (Table 1), hypertension was defined as office BP $\geq 130/80$ mmHg and ABPM $\geq 125/75$ mmHg[11], in agreement with the 2017 ACC/AHA guidelines.

Taking into consideration all the above, studies assessing the epidemiology of hypertension have previously reported the presence of this disease in > 80.0% of patients based on the office 140/90 mmHg cutoff value[12] and in 89.5% based on the office 130/80 mmHg cutoff value, with control rates among hypertensive subjects at 45.5%[13]. The prevalence of resistant hypertension in this population (office BP $\geq 130/80$ mmHg) has been previously reported in 17.5%[13] and 23.5%[14] of patients, despite intake of ≥ 1 and ≥ 3 antihypertensive drugs, respectively.

Recent guidelines recommend the use of out-of-office BP measurements as a complementary tool for improving the management of hypertension. In KTRs the wider use of ABPM has led to the recognition of abnormal diurnal BP patterns and BP phenotypes[11,15]. The rates of non-dipping status have been reported to range between 36%-95%[16-18] and that of nocturnal hypertension between 69%-77%

Table 1 Summary of guidelines for the management of hypertension in kidney transplant recipients

Ref.	Threshold for pharmacological treatment	Target blood pressure	Recommendations on 24-h ABPM	Recommendations for KTRs
Whelton <i>et al</i> [9], 2018	≥ 130/80 mmHg for primary prevention if estimated 10-yr ASCVD risk ≥ 10% and for secondary prevention if known CVD; ≥ 140/90 mmHg for primary prevention if no history of CVD and estimated 10-yr ASCVD risk < 10%	< 130/80 mmHg	Advised to exclude white coat and masked hypertension	In the absence of trials comparing different BP targets in KTRs, treatment targets for BP should probably be similar to the general CKD population; CCBs recommended as first line therapy on the basis of improved GFR and kidney survival; RAASi reserved for subset of patients with other comorbidities (proteinuria or heart failure)
KDIGO Blood Pressure Work Group[11], 2021	≥ 130/80 mmHg using standardized office BP measurement	< 130/80 mmHg using standardized office BP measurement	Out-of-office BP measurements with ABPM or home BP monitoring recommended to complement standardized office BP readings (2B)	Use of a dihydropyridine CCB or an ARB recommended as the first-line antihypertensive agent in adult KTRs (1C)

ABPM: Ambulatory blood pressure monitoring; ARB: Angiotensin receptor blocker; ASCVD: Atherosclerotic cardiovascular disease; BP: Blood pressure; CCB: Calcium channel blocker; CKD: Chronic kidney disease; CVD: Cardiovascular disease; GFR: Glomerular filtration rate; KDIGO: Kidney Disease Improving Global Outcomes; KTRs: Kidney transplant recipients; RAASi: Renin-angiotensin-aldosterone system inhibitor.

(according to the nighttime ABPM > 120/70 mmHg cutoff value for both)[18,19]. In an Italian cohort of 260 KTRs followed-up for 3.9 years, the agreement between 785 paired office and 24-h ABPM measurements was assessed, revealing significant discordance in 37% of all visits (κ -statistics = 0.25, indicating poor agreement)[19]. In 12% of all visits, patients were misclassified as hypertensive according to the office BP > 140/90 mmHg criterion while 24-h ABPM was normal according to the < 130/80 mmHg criterion (white-coat hypertension); in 25% of all visits patients were classified as normotensive according to the office criterion, while 24-h ABPM was > 130/80 mmHg (masked hypertension). In a cross-sectional study from Spain with 868 KTRs, the prevalence of white-coat and masked hypertension was 12% and 20%, respectively, applying similarly the ESC/ESH criteria[14]. Absence of systolic BP (SBP) dipping pattern was evidenced in 80% of patients. In a retrospective study, prevalence of white-coat and masked hypertension was estimated to be at 3% and 56%, respectively, with the office BP ≥ 130/80 mmHg and ABPM ≥ 125/75 mmHg thresholds[20].

In a recently published cross-sectional study with 205 KTRs[6], the prevalence of hypertension and the diagnostic performance of the two existing office BP thresholds for defining hypertension (adopted by the ESC/ESH and ACC/AHA guidelines mentioned above) was comparatively assessed. Prevalence of hypertension was 88.3% and 92.7% according to the ESC/ESH with ACC/AHA definitions for office BP measurements and 94.1% and 98.5% according to the respective ABPM thresholds. Moderate to fair agreement between office BP and 24-h ABPM was shown for both thresholds (κ -statistics = 0.52, $P < 0.001$; κ -statistics = 0.32, $P < 0.001$, respectively). Prevalence of white coat and masked hypertension was 6.7% and 39.5% using the office BP ≥ 140/90 mmHg and 5.9% and 31.7% using the office BP ≥ 130/80 mmHg threshold. Notably, ABPM revealed significantly lower control rates among hypertensive patients compared to office BP measurements using both definitions (69.6% for office *vs* 38.3% for ABPM measurements with the ESC/ESH thresholds; 43.7% *vs* 21.3% respectively with ACC/AHA thresholds).

In a sub-analysis of this study investigating presence of sex differences, the prevalence of hypertension was similar between the two genders with the office BP ≥ 130/80 mmHg threshold (93.4% for men *vs* 91.3% for women, $P = 0.589$) but significantly higher in men with the ABPM ≥ 125/75 criterion (100% *vs* 95.7%, $P = 0.014$, respectively). Prevalence of white-coat hypertension (5.1% *vs* 7.6%, $P = 0.493$) and masked hypertension (35.3% *vs* 24.2%, $P = 0.113$) did not differ significantly between men and women. The above findings underline the need for more extensive use of 24-h ABPM in KTRs, similarly to what is currently being increasingly recommended for the general population.

Association of hypertension with target organ damage

In KTRs, abnormal dipping status (non-dipping and reverse-dipping) independently predicts kidney function deterioration[21,22], while nighttime BP and night-day ratio are strongly associated with carotid-intimal media thickness[18]. Increased urinary albumin and protein excretion have been associated with hypertension in KTRs and are both independent predictors of graft loss[23-26]. Several longitudinal studies have reported an association of hypertension with left ventricular hypertrophy in KTRs, while significant reduction in left ventricular mass index (LVMI) and regression of left ventricular hypertrophy have been observed in the first 2-3 years following kidney transplantation[27,28]. However, this regression may be compromised by persistence of hypertension, high pulse pressure[27] and high sodium intake[28].

Moreover, reversal of uremic cardiomyopathy has been recently questioned according to the results of a recent meta-analysis where no difference in LVMI was detected following kidney transplantation after pooling data from four studies with 236 participants [standardized mean difference = 0.07, 95% confidence interval (CI): 0.41-0.26][29]. Masked or sustained hypertension were independent predictors for left ventricular hypertrophy in a cohort of 221 children and young adults with kidney transplant [30]. A negative association between brachial flow-mediated dilation, a marker of endothelial function, with 24-h BP and indices of BP variability has also been reported[31]. In a recently published meta-analysis pooling data from 22 studies (2078 participants), 24-h ABPM was found to be a stronger predictor of renal function decline and outperformed office BP with regards to LVMI, carotid-intimal media thickness and endothelial dysfunction markers[32]. Abnormal dipping status also identified a subgroup of KTRs at risk for target organ damage.

Prognostic impact of hypertension for adverse clinical outcomes

Hypertension in KTRs has been consistently shown to be associated with a higher incidence of kidney function decline, poor graft survival[33-38] and worse patient survival[3,34,38,39]. In the Collaborative Transplant Study, a retrospective cohort that evaluated the impact of hypertension on long-term kidney function in 29751 KTRs, a strong graded relationship between post-transplant BP and subsequent graft failure, even when patient death was censored, was reported for the first time[35]. In a subsequent sub-analysis of the Collaborative Transplant Study with data from 24404 patients, the same authors showed that SBP values consistently lower than 140 mmHg during the first 3 years post transplantation were associated with the best 10-year graft and patient outcomes; moreover successfully lowering SBP to \leq 140 mmHg even by the 3rd year was associated with better 10-year graft and death-censored survival (but not with total patient survival) compared to persistently uncontrolled BP[3].

With regards to different causes of death, changes in SBP were significantly associated with the risk of cardiovascular death only in the subgroup of patients < 50-years-old but not in older KTRs. In another retrospective cohort of 1666 patients, each rise in SBP by 10 mmHg was associated with a 12% higher risk for graft failure [relative risk (RR) = 1.12, 95%CI: 1.08-1.15], a 17% higher risk for death-censored graft failure (RR = 1.17, 95%CI: 1.12-1.22) and an 18% higher risk for death (RR = 1.18, 95%CI: 1.12-1.23), even after adjusting for acute rejection and decreased kidney failure that were previously reported to trigger BP increases and therefore further supported the independent beneficial effect of BP control[34]. Microalbuminuria and macroalbuminuria, both markers of target organ damage associated with hypertension, have been similarly shown to be independent predictors of death compared to normoalbuminuria [odds ratio (OR) = 5.55, 95%CI: 2.43-12.66; OR = 4.12, 95%CI: 1.65-10.29, respectively] [25].

With regards to specific cardiovascular events in KTRs, their burden remains high; a fact that is partly attributed to accumulation of traditional cardiovascular risk factors[40]. In a French retrospective cohort of 17526 KTRs and 3288857 non-transplanted non-dialysis participants with a 5-year follow-up, an increased incidence of myocardial infarction in the former compared to the latter (5.8% *vs* 2.8%) was shown [hazard ratio (HR) = 1.45, 95%CI: 1.35-1.55][41]. KTRs experiencing an myocardial infarction were more likely to be hypertensive than their non-KTR counterparts (76.0% *vs* 48.1%, $P < 0.0001$). Hypertension is an independent predictor of death from ischemic heart disease and major ischemic heart events, with a reported increase by 20% in the risk for death from ischemic heart disease per 10 mmHg SBP increments, during a follow-up of 5 years[39].

PATHOPHYSIOLOGY OF HYPERTENSION IN KTRs

The underlying mechanisms for development of hypertension in KTR include: (1) Traditional risk factors; (2) Those that are associated with kidney function decline; and (3) Those that are related to the kidney transplantation procedure.

Traditional risk factors

Factors considered to be associated with an increased risk of hypertension in the general population, including age, male sex, smoking status, obesity, insulin resistance and syndrome of obstructive sleep apneas, are also present in patients undergoing kidney transplantation and may be aggravated, further contributing to new-onset or worsening hypertension[42-46].

Factors associated with impaired kidney function

The same risk factors that are present in CKD populations and that are inherent to kidney function decline are also applicable in KTRs. Among those, impaired homeostatic mechanisms handling sodium and water excretion are considered a hallmark of CKD, leading to extracellular volume accumulation, hypervolemia and increased BP[5,47]. Renal sodium retention may be worsened by the use of immunosuppressive regimens, mainly corticosteroids[48] and calcineurin inhibitors (CNIs)[49] as well as during episodes of acute rejection, probably indicating ischemic allograft damage[50]. Dysregulation of the renin-angiotensin-aldosterone system[51] and sympathetic nerve overactivity, driven in the early

post transplantation period by the native kidneys (since the graft is initially denervated before becoming later re-innervated[52]), also lead to increased peripheral vascular resistance and development of hypertension[5,53,54]. Increased arterial stiffness, endothelial dysfunction and imbalance between vasoconstrictive and vasodilating agents are also pertinent to CKD and further contribute to increased BP[55,56].

Factors associated with kidney transplantation

Immunosuppressive regimens: Most current protocols for prevention of transplant rejection include as maintenance therapy a combination of a CNI (cyclosporine or tacrolimus) with either a purine pathway inhibitor that subsequently blocks lymphocyte proliferation (mycophenolate mofetil or azathioprine) or a mammalian target of rapamycin inhibitor (everolimus or sirolimus), with or without corticosteroids [57]. While mycophenolate mofetil and mammalian target of rapamycin inhibitors are considered low risk agents, corticosteroids and CNIs potentially trigger hypertension and other major comorbidities in KTRs[58,57].

The burden of long-term corticosteroid exposure on corticosteroid-related adverse events and healthcare economic costs has been previously explored in the general population, as well as in KTRs, with prevalence of corticosteroid-induced hypertension estimated to exceed 30% of the total population [59] and hospitalization costs to be 2.2-fold higher in the steroid-maintenance group than in the steroid-free group 1-year post living-donor kidney transplantation[60]. According to the results of a meta-analysis (34 studies, 5637 patients), complete steroid avoidance or withdrawal reduces the risk of incident hypertension and diabetes with no significant effect on graft or patient survival[61]. The main cause of corticosteroid-induced hypertension is associated with partial activation of mineralocorticoid receptors by cortisol causing urinary sodium and water retention and therefore volume expansion[5]. This mechanism has been however called into question, and a similarly important role of glucocorticoid receptors in vascular smooth cells has been proposed[62], leading to an increase in peripheral vascular resistance through attenuation of vascular response to vasodilators (nitric oxide) and upregulation of the angiotensin II receptor[48].

The mechanisms of CNI-induced hypertension are multifactorial and involve impaired sodium and water excretion, upregulation of vasoconstrictive agents (prostaglandins, thromboxane, endothelin-1), downregulation of vasodilating prostaglandins and alterations in regulation of intracellular calcium ions, leading to vasoconstriction of afferent arteriole, a decrease in glomerular filtration rate (GFR) and an increase in peripheral vascular resistance[49,63-66]. Tacrolimus has been associated with a lower incidence of hypertension[67,68] but a higher risk for new-onset diabetes compared to cyclosporine[69,70].

After complete withdrawal of CNIs was abandoned due to an increased risk of biopsy-proven acute rejection episodes[71], reduction of their dose was explored in an attempt to minimize their toxic effects. In an open-label RCT, 1645 KTRs were randomly allocated to receive standard-dose cyclosporine (target trough level 150-300 ng/mL for the first 3 mo; 100-200 ng/mL thereafter), low-dose cyclosporine (target trough level 50-100 ng/mL throughout the study), low-dose tacrolimus (target trough level 3-7 ng/mL throughout the study) or low-dose sirolimus (target trough level 4-8 ng/mL throughout the study) for 12 mo[72]. Patients in all treatment groups received mycophenolate mofetil and corticosteroids; those randomized to low-dose regimens followed a 2-mo induction treatment with daclizumab. At study-end, patients in the low-dose tacrolimus group had the highest estimated GFR (65.4 mL/min) and highest rates of allograft survival (94.2%), followed by low-dose cyclosporine (93.1%), standard-dose cyclosporine (89.3%) and low-dose sirolimus (89.3%) ($P = 0.02$), therefore providing further evidence in favor of low-dose tacrolimus regimens.

Accordingly, it is usually recommended to use minimal dosages of steroids (for example, 5 mg per day dose of prednisone) to achieve long-term immunosuppression in organ transplant patients without increasing the risk for hypertension[42]. Belatacept is another biologic immunosuppressive agent that acts by inhibiting T cell co-stimulation, approved by the United States Food and Drug Administration since 2011 on the basis of evidence of non-inferiority in preventing acute rejection in KTRs provided from three RCTs comparing belatacept to cyclosporine[69,73,74]. According to a meta-analysis (5 studies, 1535 participants), use of belatacept has been associated with lower BP levels and reduced incidence of chronic kidney scarring compared to CNIs[75].

Donor/recipient factors: Donor's age represents a major risk factor for development of post-transplant hypertension[23], along with considerable discrepancies in somatometric characteristics between donors and graft recipients (female to male transplantation, pediatric to adult transplantation, low donor/recipient body weight ratio), leading to a phenomenon of "underdosing" due to reduced donor nephron mass compared to recipient needs[76,77]. These differences result in hyperfiltration, glomerular hypertrophy and increased intraglomerular pressure.

Pre-existing donor hypertension is also associated with an increased risk for post transplantation hypertension and allograft dysfunction[23,78]. Transplant recipients from donors with a family history of hypertension face a 10-fold higher risk of requiring antihypertensive treatment compared to recipients from a normotensive family[79]. Recipients of transplants from expanded criteria donors (age > 60 or 50-59 with two of the following: History of hypertension; serum creatinine > 1.5 mg/dL;

cerebrovascular death) also experience a higher risk for hypertension post transplantation[80].

Other factors related to donors, predisposing to delayed graft function and increased nephrotoxicity, that could be possibly associated with development of hypertension in KTRs include the presence of genetic variants that affect the expression of cytochrome P450 3A5, apolipoprotein L1, P-glycoprotein and multidrug resistance protein 2[81-83]. With regards to recipient factors, the presence of native kidneys may further contribute to BP increments probably due to renin secretion[84]. Moreover, longstanding hypertension may be present in many recipients before transplantation, as progression of CKD is associated with atheromatosis of middle-sized conduit arteries and most importantly with reduced compliance and arterial stiffness of the aorta and the large arteries[85]. This vascular remodeling may not be fully reversible after kidney transplantation.

Transplant renal artery stenosis: Prevalence of transplant renal artery stenosis (TRAS) reportedly ranged in the past between 1%-23%, with a significant increase noted in diagnosed cases with the use of non-invasive imaging techniques[86]. Refractory hypertension and worsening kidney function are the main clinical manifestations of TRAS, which usually develops 3-24 mo post transplantation and is associated with an increased risk of graft loss[84].

With regards to the anatomic site, the stenosis can be: (1) Anastomotic (due to vascular damage at the time of surgery); (2) Proximal (due to recipient's atherosclerosis); and (3) Distal (with a non-fully elucidated pathogenesis related to mechanical and immunological factors)[87]. Since the recipient's iliac artery and not the abdominal aorta is the most common site of donor renal artery anastomosis, this connection between smaller arteries is prone to narrowing and subsequent development of TRAS pathophysiology, involving impediment of blood flow, renal hypoperfusion and activation of the renin-angiotensin-aldosterone system[84].

Immunological factors leading to TRAS include immune-mediated vascular endothelial injury[88] and development of *de novo* class II donor-specific antibodies[89]. The association between TRAS and cytomegalovirus infection[90], as well as ischemia/reperfusion injury, has also been reported[91]. In the absence of an RCT comparing endovascular angioplasty with or without stenting *vs* surgical vascularization in KTRs, angioplasty is the preferred treatment of TRAS with reported rates of clinical success (improvements in BP or kidney function) between 65.5%-94.0% and of technical success > 90%[92].

Acute and chronic kidney dysfunction: Kidney function decline, whether in the context of an episode of acute cellular and antibody rejection or due to chronic allograft nephropathy, has been associated with new or worsening hypertension, with the evidence of a cause-effect relationship still inconclusive [42,84,93,94]. Acute rejection may trigger new-onset hypertension, probably *via* activation of the renin-angiotensin system according to the patient's volume status. In this case, treatment of rejection is accompanied by improvement in BP levels, whereas hypertension that is not associated to acute rejection would be further deteriorated with modifications in doses of immunosuppression[94].

Recurrence of the primary glomerular disease, tubular atrophy, interstitial fibrosis, chronic antibody-mediated organ rejection, development of non-HLA agonistic anti-angiotensin-II type 1 receptor antibodies and thrombotic microangiopathy are the major contributors to chronic allograft injury leading to sudden rises of BP[5,84,94,95]. Patients with positive angiotensin-II type 1 receptor antibodies represent a subset of those with antibody-mediated rejection in whom kidney dysfunction is associated with malignant hypertension and acute vascular lesions on biopsy. A clinicopathological entity including seizures on top of malignant hypertension and vasculopathy has also been described, bearing resemblance to pre-eclamptic syndromes where angiotensin-II type 1 receptor antibodies have been previously reported[95].

HYPERTENSION TREATMENT IN KTRs

Targets of BP therapy

Historically, no universal agreement has been achieved with regards to BP targets in CKD and more particularly in kidney transplantation, similarly to the heterogeneity observed in different BP thresholds used for diagnosis of hypertension[7-11]. In the absence of specific focus on KTRs, the BP targets of CKD population were expected to be endorsed; according to the 2018 ESC/ESH guidelines in patients with CKD the respective recommendation was lowering BP to < 140/90 mmHg and towards 130/80 mmHg [10]. However in the latest 2017 ACC/AHA and 2021 Kidney Disease Improving Global Outcomes guidelines specific recommendations targeting BP less than 130/80 mmHg have been provided for KTRs[9,11].

Non-pharmacological measures

In the absence of evidence focused on KTRs, lifestyle modifications should be adopted as a first-line approach on the basis of recommendations applied in the general population since these interventions provide general health benefits that extend beyond BP control[96]. Low sodium intake (< 2 g/d), moderate-intensity physical activity (≥ 150 min/wk), adoption of a balanced diet and maintenance of

body mass index and waist circumference within normal range (18.5 and 24.9 kg/m² and < 102 cm, respectively), reduction in alcohol consumption and smoking cessation are encompassed by most hypertension guidelines[5,9-11,97].

Pharmacological measures

In CKD populations, use of an angiotensin-converting enzyme inhibitors (ACEi) or an angiotensin receptor blocker (ARB) has been established as first-line treatment, followed by combinations with a calcium channel blocker (CCB) and/or diuretic[98]. In KTRs, the use of a dihydropyridine CCB is commonly advocated notably in the early post transplantation period because of their demonstrated efficacy in improving graft function and minimizing the vasoconstrictive effects of CNIs[15,93,99]. To support this choice, CCBs have been uniformly associated with improved patient and graft outcomes in several studies[99-103]. In contrast, the use of ACEis/ARBs in KTRs was considered a source of controversy for many years[4]. Treatment with an ACEi/ARB led to impressively better patient (HR = 0.57; 95%CI: 0.40-0.81) and graft (HR = 0.56; 95%CI: 0.40-0.78) survival rates in a retrospective cohort with 2031 KTRs[104] but not in a subsequent analysis of data from 17208 KTRs[105].

According to the results of an RCT with 154 hypertensive KTRs allocated to receive nifedipine 30 mg or lisinopril 10 mg 3 wk post transplantation, no differences were noted in BP control. Nevertheless, a significant increase was observed in measured GFR for nifedipine compared to lisinopril (mean between-group difference 9.6 mL/min, 95%CI: 5.5-13.7 mL/min) at 1 year, an improvement that was maintained at 2 years[106]. The results of a 2009 Cochrane systematic review claimed that patients receiving ACEis were exposed to a higher risk of hyperkalemia and anemia and that in direct comparison with CCBs their use was associated with worse kidney function (mean between-group difference for estimated GFR -11.48 mL/min, 95%CI: -15.75 to -7.21).

Data on graft loss were available from only one study showing no significant differences (RR = 7.37, 95%CI: 0.39-140.35)[100]. Among the main limitations of this meta-analysis was the fact that data for head-to-head comparisons were pooled from six studies with only 296 participants; four of them had a follow-up between 4 wk and 6 mo[25,107-109], two of them were published after the year 2000[25,106], and no one compared ARBs to CCBs directly. In a more recent meta-analysis conducted by Pisano *et al* [99] pooling data from 71 RCTs and providing evidence on both ACEis and ARBs, a significant reduction in the risk for graft loss was observed by 42% with CCBs (16 studies, 1327 participants) and by 38% with ACEi/ARBs (9 studies, 1246 participants).

When pooling results from head-to-head comparisons between CCBs and ACEis/ARBs, an increase in GFR (11.07 mL/min, 95%CI: 6.04-16.09) was noted for CCBs, along with a reduction in serum potassium levels (-0.24 mEq/L, 95%CI: -0.38 to -0.10). In the 2021 Kidney Disease Improving Global Outcomes guidelines, use of a dihydropyridine CCB or an ARB has received a grade 1C recommendation for first-line treatment in KTRs, with potential benefits on graft survival (RR for graft loss compared to placebo: Dihydropyridine CCBs 0.62, 95%CI: 0.43-0.90; ARBs: 0.35, 95%CI: 0.15-0.84) outweighing side effects related to each class of agent[11]. No significant effect on mortality or cardiovascular events was detected with either of these classes.

CONCLUSION

The accurate diagnosis of hypertension and adequate BP control in KTRs remains an area of controversy among different guidelines, with BP thresholds and treatment goals mostly extrapolated from CKD populations. The diagnostic performance of office measurements has been recently questioned, with more recent studies using ABPM suggesting a higher prevalence of uncontrolled, masked and nocturnal hypertension in KTRs than previously believed that is further increased when the new lower BP thresholds are applied. Recent analyses provide evidence that 24-h ABPM outperforms office BP measurements with regards to markers of target organ damage, including LVMI, carotid-intimal media thickness and flow-mediated dilation, and represents an independent predictor of kidney function decline and graft loss.

Except from pre-existing or *de novo* traditional risk factors and factors associated with CKD, immunosuppressive drugs, donor-recipient mismatches, TRAS, recurrence of primary glomerular disease, presence of native kidneys as well as episodes of acute and chronic allograft injury contribute to development of hypertension post transplantation. Recent guidelines recommend the use of dihydropyridine CCBs[15], as they exhibit a favorable profile due to their vasodilatory effects counteracting vasoconstriction induced by CNIs and their favorable effects on outcomes, or ARBs due to their favorable effects on graft survival, despite previously reported undesirable effects on risk of hyperkalemia and anemia. High-quality large-scale RCTs comparatively assessing the effect of different antihypertensive agents on mortality and major cardiovascular events are warranted to provide definite evidence.

FOOTNOTES

Author contributions: Sarafidis P and Ferro CJ conceived and designed the work; Alexandrou ME and Ferro CJ performed the bibliography search; Alexandrou ME, Ferro CJ and Sarafidis P prepared the original draft; Boletis I and Papagianni A critically revised the manuscript; Sarafidis P supervised the project; and all authors have read and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Greece

ORCID number: Maria-Eleni Alexandrou 0000-0003-3526-261X; Aikaterini Papagianni 0000-0003-0437-5208; Pantelis Sarafidis 0000-0002-9174-4018.

S-Editor: Wang JJ

L-Editor: Filipodia

P-Editor: Wang JJ

REFERENCES

- 1 **Rangaswami J**, Mathew RO, Parasuraman R, Tantisattamo E, Lubetzky M, Rao S, Yaqub MS, Birdwell KA, Bennett W, Dalal P, Kapoor R, Lerma EV, Lerman M, McCormick N, Bangalore S, McCullough PA, Dadhania DM. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. *Nephrol Dial Transplant* 2019; **34**: 760-773 [PMID: 30984976 DOI: 10.1093/ndt/gfz053]
- 2 **Ying T**, Shi B, Kelly PJ, Pilmore H, Clayton PA, Chadban SJ. Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. *J Am Soc Nephrol* 2020; **31**: 2887-2899 [PMID: 32908001 DOI: 10.1681/ASN.2020050566]
- 3 **Opelz G**, Döhler B; Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. *Am J Transplant* 2005; **5**: 2725-2731 [PMID: 16212633 DOI: 10.1111/j.1600-6143.2005.01093.x]
- 4 **Halimi JM**, Persu A, Sarafidis PA, Burnier M, Abramowicz D, Sautenet B, Oberbauer R, Mallamaci F, London G, Rossignol P, Wuerzner G, Watschinger B, Zoccali C. Optimizing hypertension management in renal transplantation: a call to action. *Nephrol Dial Transplant* 2017; **32**: 1959-1962 [PMID: 29099945 DOI: 10.1093/ndt/gfx283]
- 5 **Ponticelli C**, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. *Transpl Int* 2011; **24**: 523-533 [PMID: 21382101 DOI: 10.1111/j.1432-2277.2011.01242.x]
- 6 **Korogiannou M**, Sarafidis P, Theodorakopoulou MP, Alexandrou ME, Xagas E, Boletis IN, Marinaki S. Diagnostic Performance of Office versus Ambulatory Blood Pressure in Kidney Transplant Recipients. *Am J Nephrol* 2021; **52**: 548-558 [PMID: 34311458 DOI: 10.1159/000517358]
- 7 **Castillo-Rodriguez E**, Fernandez-Fernandez B, Alegre-Bellascá R, Kanbay M, Ortiz A. The chaos of hypertension guidelines for chronic kidney disease patients. *Clin Kidney J* 2019; **12**: 771-777 [PMID: 31807290 DOI: 10.1093/ckj/sfz126]
- 8 **Carriazo S**, Sarafidis P, Ferro CJ, Ortiz A. Blood pressure targets in CKD 2021: the never-ending guidelines debacle. *Clin Kidney J* 2022; **15**: 845-851 [PMID: 35498896 DOI: 10.1093/ckj/sfac014]
- 9 **Whelton PK**, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Oviagele B, Smith SC, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension* 2018; **71**: 1269-1324 [DOI: 10.1161/HYP.0000000000000065]
- 10 **Williams B**, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens* 2018; **36**: 1953-2041 [PMID: 30234752 DOI: 10.1097/HJH.0000000000001940]
- 11 **Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group**. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int* 2021; **99**: S1-S87 [PMID: 33637192 DOI: 10.1016/j.kint.2020.11.003]
- 12 **Campistol JM**, Romero R, Paul J, Gutiérrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant

- patients: changes over the last decade. *Nephrol Dial Transplant* 2004; **19** Suppl 3: iii62-iii66 [PMID: [15192139](#) DOI: [10.1093/ndt/gfh1018](#)]
- 13 **Vetromile F**, Pernin V, Szwarc I, Garrigue V, Delmas S, Mourad G, Fesler P. Prevalence and risk factors of noncontrolled and resistant arterial hypertension in renal transplant recipients. *Transplantation* 2015; **99**: 1016-1022 [PMID: [25393160](#) DOI: [10.1097/TP.0000000000000467](#)]
 - 14 **Arias-Rodríguez M**, Fernández-Fresnedo G, Campistol JM, Marín R, Franco A, Gómez E, Cabello V, Díaz JM, Osorio JM, Gallego R; RETENAL Group (Control of Resistant Hypertension in Renal Transplant. Prevalence, Significance). Prevalence and clinical characteristics of renal transplant patients with true resistant hypertension. *J Hypertens* 2015; **33**: 1074-1081 [PMID: [25668343](#) DOI: [10.1097/HJH.0000000000000510](#)]
 - 15 **Halimi JM**, Ortiz A, Sarafidis PA, Mallamaci F, Wuerzner G, Pisano A, London G, Persu A, Rossignol P, Sautenet B, Ferro C, Boletis J, Kanaan N, Vogt L, Bolignano D, Burnier M, Zoccali C. Hypertension in kidney transplantation: a consensus statement of the 'hypertension and the kidney' working group of the European Society of Hypertension. *J Hypertens* 2021; **39**: 1513-1521 [PMID: [34054055](#) DOI: [10.1097/HJH.0000000000002879](#)]
 - 16 **Kooman JP**, Christiaans MH, Boots JM, van Der Sande FM, Leunissen KM, van Hooff JP. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. *Am J Kidney Dis* 2001; **37**: 1170-1176 [PMID: [11382685](#) DOI: [10.1053/ajkd.2001.24518](#)]
 - 17 **Wen KC**, Gourishankar S. Evaluating the utility of ambulatory blood pressure monitoring in kidney transplant recipients. *Clin Transplant* 2012; **26**: E465-E470 [PMID: [23061756](#) DOI: [10.1111/ctr.12009](#).]
 - 18 **Mallamaci F**, Tripepi R, Leonardis D, Mafrica A, Versace MC, Provenzano F, Tripepi G, Zoccali C. Nocturnal Hypertension and Altered Night-Day BP Profile and Atherosclerosis in Renal Transplant Patients. *Transplantation* 2016; **100**: 2211-2218 [PMID: [26683511](#) DOI: [10.1097/TP.0000000000001023](#)]
 - 19 **Mallamaci F**, Tripepi R, D'Arrigo G, Porto G, Versace MC, Marino C, Sanguedolce MC, Testa A, Tripepi G, Zoccali C. Long-term blood pressure monitoring by office and 24-h ambulatory blood pressure in renal transplant patients: a longitudinal study. *Nephrol Dial Transplant* 2019; **34**: 1558-1564 [PMID: [30476170](#) DOI: [10.1093/ndt/gfy355](#)]
 - 20 **Ahmed J**, Ozorio V, Farrant M, Van Der Merwe W. Ambulatory vs office blood pressure monitoring in renal transplant recipients. *J Clin Hypertens (Greenwich)* 2015; **17**: 46-50 [PMID: [25440573](#) DOI: [10.1111/jch.12448](#)]
 - 21 **Ibernón M**, Moreso F, Sarrias X, Sarrias M, Grinyó JM, Fernandez-Real JM, Ricart W, Serón D. Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation. *Nephrol Dial Transplant* 2012; **27**: 2089-2095 [PMID: [22015441](#) DOI: [10.1093/ndt/gfr587](#)]
 - 22 **Wadei HM**, Amer H, Griffin MD, Taler SJ, Stegall MD, Textor SC. Abnormal circadian blood pressure pattern 1-year after kidney transplantation is associated with subsequent lower glomerular filtration rate in recipients without rejection. *J Am Soc Hypertens* 2011; **5**: 39-47 [PMID: [21269908](#) DOI: [10.1016/j.jash.2010.11.004](#)]
 - 23 **Ducloux D**, Motte G, Kribs M, Abdelfatah AB, Bresson-Vautrin C, Rebibou JM, Chalopin JM. Hypertension in renal transplantation: donor and recipient risk factors. *Clin Nephrol* 2002; **57**: 409-413 [PMID: [12078942](#) DOI: [10.5414/cnp57409](#)]
 - 24 **Fernández-Fresnedo G**, Plaza JJ, Sánchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. *Nephrol Dial Transplant* 2004; **19** Suppl 3: iii47-iii51 [PMID: [15192136](#) DOI: [10.1093/ndt/gfh1015](#)]
 - 25 **Halimi JM**, Buchler M, Al-Najjar A, Laouad I, Chatelet V, Marlière JF, Nivet H, Lebranchu Y. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. *Am J Transplant* 2007; **7**: 618-625 [PMID: [17217438](#) DOI: [10.1111/j.1600-6143.2007.01665.x](#)]
 - 26 **Halimi JM**. Albuminuria, proteinuria, and graft survival in kidney transplantation. *Am J Kidney Dis* 2011; **58**: 1037; author reply 1037-1037; author reply 1038 [PMID: [22099571](#) DOI: [10.1053/j.ajkd.2011.09.003](#)]
 - 27 **Rigatto C**, Foley RN, Kent GM, Guttmann R, Parfrey PS. Long-term changes in left ventricular hypertrophy after renal transplantation. *Transplantation* 2000; **70**: 570-575 [PMID: [10972211](#) DOI: [10.1097/00007890-200008270-00006](#)]
 - 28 **du Cailar G**, Oudot C, Fesler P, Mimran A, Bonnet B, Pernin V, Ribstein J, Mourad G. Left ventricular mass changes after renal transplantation: influence of dietary sodium and change in serum uric acid. *Transplantation* 2014; **98**: 202-207 [PMID: [24926832](#) DOI: [10.1097/TP.0000000000000043](#)]
 - 29 **Pickup LC**, Law JP, Radhakrishnan A, Price AM, Loutradis C, Smith TO, Edwards NC, Steeds RP, Townend JN, Ferro CJ. Changes in left ventricular structure and function associated with renal transplantation: a systematic review and meta-analysis. *ESC Heart Fail* 2021; **8**: 2045-2057 [PMID: [33987986](#) DOI: [10.1002/ehf2.13283](#)]
 - 30 **Hamdani G**, Nehus EJ, Hanevold CD, Sebestyen Van Sickle J, Woroniecki R, Wenderfer SE, Hooper DK, Blowey D, Wilson A, Warady BA, Mitsnefes MM. Ambulatory Blood Pressure, Left Ventricular Hypertrophy, and Allograft Function in Children and Young Adults After Kidney Transplantation. *Transplantation* 2017; **101**: 150-156 [PMID: [26895218](#) DOI: [10.1097/TP.0000000000001087](#)]
 - 31 **Ozkayar N**, Altun B, Yildirim T, Yilmaz R, Dede F, Arik G, Turkmen E, Hayran M, Aki FT, Arici M, Erdem Y. Blood pressure measurements, blood pressure variability and endothelial function in renal transplant recipients. *Clin Exp Hypertens* 2014; **36**: 392-397 [PMID: [24047335](#) DOI: [10.3109/10641963.2013.827706](#)]
 - 32 **Pisano A**, Mallamaci F, D'Arrigo G, Bolignano D, Wuerzner G, Ortiz A, Burnier M, Kanaan N, Sarafidis P, Persu A, Ferro CJ, Loutradis C, Boletis IN, London G, Halimi JM, Sautenet B, Rossignol P, Vogt L, Zoccali C. Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. *Nephrol Dial Transplant* 2021 [PMID: [33764450](#) DOI: [10.1093/ndt/gfab076](#)]
 - 33 **Ponticelli C**, Montagnino G, Aroldi A, Angelini C, Braga M, Tarantino A. Hypertension after renal transplantation. *Am J Kidney Dis* 1993; **21**: 73-78 [PMID: [8494023](#) DOI: [10.1016/0272-6386\(93\)70098-j](#)]
 - 34 **Kasiske BL**, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B, O'Shaughnessy EA, Dahl DC, Silkensen JR, Sahadevan M, Snyder JJ. Hypertension after kidney transplantation. *Am J Kidney Dis* 2004; **43**: 1071-1081 [PMID: [15168388](#) DOI: [10.1053/j.ajkd.2004.03.013](#)]
 - 35 **Opelz G**, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative

- Transplant Study. *Kidney Int* 1998; **53**: 217-222 [PMID: 9453022 DOI: 10.1046/j.1523-1755.1998.00744.x]
- 36 **Mange KC**, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. *JAMA* 2000; **283**: 633-638 [PMID: 10665703 DOI: 10.1001/jama.283.5.633]
 - 37 **Mange KC**, Feldman HI, Joffe MM, Fa K, Bloom RD. Blood pressure and the survival of renal allografts from living donors. *J Am Soc Nephrol* 2004; **15**: 187-193 [PMID: 14694172 DOI: 10.1097/01.asn.0000104574.04006.08]
 - 38 **Tutone VK**, Mark PB, Stewart GA, Tan CC, Rodger RS, Geddes CC, Jardine AG. Hypertension, antihypertensive agents and outcomes following renal transplantation. *Clin Transplant* 2005; **19**: 181-192 [PMID: 15740553 DOI: 10.1111/j.1399-0012.2004.00315.x]
 - 39 **Aakhus S**, Dahl K, Widerøe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. *Clin Transplant* 2004; **18**: 596-604 [PMID: 15344967 DOI: 10.1111/j.1399-0012.2004.00235.x]
 - 40 **Díaz JM**, Gich I, Bonfill X, Solà R, Guirado L, Facundo C, Sainz Z, Puig T, Silva I, Ballarín J. Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival. *Transplant Proc* 2009; **41**: 2151-2155 [PMID: 19715859 DOI: 10.1016/j.transproceed.2009.06.134]
 - 41 **Didier R**, Yao H, Legendre M, Halimi JM, Rebibou JM, Herbert J, Zeller M, Fauchier L, Cottin Y. Myocardial Infarction after Kidney Transplantation: A Risk and Specific Profile Analysis from a Nationwide French Medical Information Database. *J Clin Med* 2020; **9** [PMID: 33086719 DOI: 10.3390/jcm9103356]
 - 42 **Loutradis C**, Sarafidis P, Marinaki S, Berry M, Borrows R, Sharif A, Ferro CJ. Role of hypertension in kidney transplant recipients. *J Hum Hypertens* 2021; **35**: 958-969 [PMID: 33947943 DOI: 10.1038/s41371-021-00540-5]
 - 43 **Workeneh B**, Moore LW, Nolte Fong JV, Shypailo R, Gaber AO, Mitch WE. Successful Kidney Transplantation Is Associated With Weight Gain From Truncal Obesity and Insulin Resistance. *J Ren Nutr* 2019; **29**: 548-555 [PMID: 30852120 DOI: 10.1053/j.jrn.2019.01.009]
 - 44 **Lafranca JA**, IJermans JN, Betjes MG, Dor FJ. Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. *BMC Med* 2015; **13**: 111 [PMID: 25963131 DOI: 10.1186/s12916-015-0340-5]
 - 45 **Molnar MZ**, Lazar AS, Lindner A, Fornadi K, Czira ME, Dunai A, Zoller R, Szentkiralyi A, Rosivall L, Shapiro CM, Novak M, Mucsi I. Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients. *Clin J Am Soc Nephrol* 2010; **5**: 125-132 [PMID: 19965541 DOI: 10.2215/CJN.04030609]
 - 46 **Mallamaci F**, Tripepi R, D'Arrigo G, Panuccio V, Parlongo G, Caridi G, Versace MC, Parati G, Tripepi G, Zoccali C. Sleep-Disordered Breathing and 24-Hour Ambulatory Blood Pressure Monitoring in Renal Transplant Patients: Longitudinal Study. *J Am Heart Assoc* 2020; **9**: e016237 [PMID: 32578469 DOI: 10.1161/JAHA.120.016237]
 - 47 **Chan W**, Bosch JA, Jones D, McTernan PG, Inston N, Moore S, Kaur O, Phillips AC, Borrows R. Hypervolemia and blood pressure in prevalent kidney transplant recipients. *Transplantation* 2014; **98**: 320-327 [PMID: 24770615 DOI: 10.1097/TP.000000000000066]
 - 48 **Goodwin JE**, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. *J Am Soc Nephrol* 2008; **19**: 1291-1299 [PMID: 18434569 DOI: 10.1681/ASN.2007080911]
 - 49 **Esteve-Font C**, Ars E, Guillen-Gomez E, Campistol JM, Sanz L, Jiménez W, Knepper MA, Torres F, Torra R, Ballarín JA, Fernández-Llama P. Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2). *Nephrol Dial Transplant* 2007; **22**: 2810-2816 [PMID: 17595192 DOI: 10.1093/ndt/gfm390]
 - 50 **Cosio FG**, Pelletier RP, Pesavento TE, Henry ML, Ferguson RM, Mitchell L, Lemeshow S. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. *Kidney Int* 2001; **59**: 1158-1164 [PMID: 11231374 DOI: 10.1046/j.1523-1755.2001.0590031158.x]
 - 51 **Kovarik JJ**, Kaltenecker CC, Kopecky C, Domenig O, Antlanger M, Werzowa J, Eskandary F, Kain R, Poglitsch M, Schmaldienst S, Böhmig GA, Säemann MD. Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation. *Sci Rep* 2019; **9**: 9762 [PMID: 31278281 DOI: 10.1038/s41598-019-46114-x]
 - 52 **Gazdar AF**, Dammin GJ. Neural degeneration and regeneration in human renal transplants. *N Engl J Med* 1970; **283**: 222-224 [PMID: 4912789 DOI: 10.1056/NEJM197007302830502]
 - 53 **Siragy HM**, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. *Am J Nephrol* 2010; **31**: 541-550 [PMID: 20484892 DOI: 10.1159/000313363]
 - 54 **Kaur J**, Young BE, Fadel PJ. Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. *Int J Mol Sci* 2017; **18** [PMID: 28767097 DOI: 10.3390/ijms18081682]
 - 55 **Chue CD**, Townsend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. *Heart* 2010; **96**: 817-823 [PMID: 20406771 DOI: 10.1136/hrt.2009.184879]
 - 56 **Moody WE**, Edwards NC, Madhani M, Chue CD, Steeds RP, Ferro CJ, Townsend JN. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? *Atherosclerosis* 2012; **223**: 86-94 [PMID: 22349087 DOI: 10.1016/j.atherosclerosis.2012.01.043]
 - 57 **Kalluri HV**, Hardinger KL. Current state of renal transplant immunosuppression: Present and future. *World J Transplant* 2012; **2**: 51-68 [PMID: 24175197 DOI: 10.5500/wjt.v2.i4.51]
 - 58 **Morales JM**. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. *Kidney Int Suppl* 2002; **S81-S87** [PMID: 12410861 DOI: 10.1046/j.1523-1755.62.s82.16.x]
 - 59 **Rice JB**, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. *Clin Ther* 2017; **39**: 2216-2229 [PMID: 29055500 DOI: 10.1016/j.clinthera.2017.09.011]
 - 60 **Gheith OA**, Nematalla AH, Bakr MA, Refaie A, Shokeir AA, Ghoneim MA. Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study. *Exp Clin Transplant* 2011; **9**: 121-127 [PMID: 21453230]
 - 61 **Knight SR**, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. *Transplantation* 2010; **89**: 1-14 [PMID: 20061913 DOI: 10.1097/TP.0b013e3181e518cc]
 - 62 **Baum M**, Moe OW. Glucocorticoid-mediated hypertension: does the vascular smooth muscle hold all the answers? *J Am Soc Nephrol* 2008; **19**: 1251-1253 [PMID: 18508960 DOI: 10.1681/ASN.2008040410]

- 63 **Textor SC**, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RA. Cyclosporine-induced hypertension after transplantation. *Mayo Clin Proc* 1994; **69**: 1182-1193 [PMID: 7967781 DOI: [10.1016/s0025-6196\(12\)65772-3](https://doi.org/10.1016/s0025-6196(12)65772-3)]
- 64 **Miller LW**. Cardiovascular toxicities of immunosuppressive agents. *Am J Transplant* 2002; **2**: 807-818 [PMID: 12392286 DOI: [10.1034/j.1600-6143.2002.20902.x](https://doi.org/10.1034/j.1600-6143.2002.20902.x)]
- 65 **Hoorn EJ**, Walsh SB, McCormick JA, Fürstenberg A, Yang CL, Roeschel T, Paliege A, Howie AJ, Conley J, Bachmann S, Unwin RJ, Ellison DH. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. *Nat Med* 2011; **17**: 1304-1309 [PMID: 21963515 DOI: [10.1038/nm.2497](https://doi.org/10.1038/nm.2497)]
- 66 **Remuzzi G**, Perico N. Cyclosporine-induced renal dysfunction in experimental animals and humans. *Kidney Int Suppl* 1995; **52**: S70-S74 [PMID: 8587288]
- 67 **Artz MA**, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Moons P, Borm G, Hilbrands LB. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. *Am J Transplant* 2004; **4**: 937-945 [PMID: 15147428 DOI: [10.1111/j.1600-6143.2004.00427.x](https://doi.org/10.1111/j.1600-6143.2004.00427.x)]
- 68 **Morales JM**, Domínguez-Gil B. Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation. *J Am Soc Nephrol* 2006; **17**: S296-S303 [PMID: 17130278 DOI: [10.1681/ASN.2006080930](https://doi.org/10.1681/ASN.2006080930)]
- 69 **Vincenti F**, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N; DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. *Am J Transplant* 2007; **7**: 1506-1514 [PMID: 17359512 DOI: [10.1111/j.1600-6143.2007.01749.x](https://doi.org/10.1111/j.1600-6143.2007.01749.x)]
- 70 **Heisel O**, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. *Am J Transplant* 2004; **4**: 583-595 [PMID: 15023151 DOI: [10.1046/j.1600-6143.2003.00372.x](https://doi.org/10.1046/j.1600-6143.2003.00372.x)]
- 71 **Ekberg H**, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. *Am J Transplant* 2007; **7**: 560-570 [PMID: 17229079 DOI: [10.1111/j.1600-6143.2006.01645.x](https://doi.org/10.1111/j.1600-6143.2006.01645.x)]
- 72 **Ekberg H**, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 2007; **357**: 2562-2575 [PMID: 18094377 DOI: [10.1056/NEJMoa067411](https://doi.org/10.1056/NEJMoa067411)]
- 73 **Vincenti F**, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). *Am J Transplant* 2010; **10**: 535-546 [PMID: 20415897 DOI: [10.1111/j.1600-6143.2009.03005.x](https://doi.org/10.1111/j.1600-6143.2009.03005.x)]
- 74 **Durrbach A**, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). *Am J Transplant* 2010; **10**: 547-557 [PMID: 20415898 DOI: [10.1111/j.1600-6143.2010.03016.x](https://doi.org/10.1111/j.1600-6143.2010.03016.x)]
- 75 **Masson P**, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. *Cochrane Database Syst Rev* 2014; CD010699 [PMID: 25416857 DOI: [10.1002/14651858.CD010699.pub2](https://doi.org/10.1002/14651858.CD010699.pub2)]
- 76 **Brenner BM**, Milford EL. Nephron underdosing: a programmed cause of chronic renal allograft failure. *Am J Kidney Dis* 1993; **21**: 66-72 [PMID: 8494022 DOI: [10.1016/0272-6386\(93\)70097-i](https://doi.org/10.1016/0272-6386(93)70097-i)]
- 77 **el-Agroudy AE**, Hassan NA, Bakr MA, Foda MA, Shokeir AA, Shehab el-Dein AB. Effect of donor/recipient body weight mismatch on patient and graft outcome in living-donor kidney transplantation. *Am J Nephrol* 2003; **23**: 294-299 [PMID: 12902614 DOI: [10.1159/000072819](https://doi.org/10.1159/000072819)]
- 78 **Altheaby A**, Al Dalbhi S, Alghamdi Y, Almigbal TH, Alotaibi KN, Batais MA, Alodhayani A, Alkushail A, Alhantoushi M, Alsaad SM. Effect of donor hypertension on renal transplant recipients' blood pressure, allograft outcomes and survival: a systematic review and meta-analysis. *Am J Cardiovasc Dis* 2019; **9**: 49-58 [PMID: 31516763]
- 79 **Guidi E**, Menghetti D, Milani S, Montagnino G, Palazzi P, Bianchi G. Hypertension may be transplanted with the kidney in humans: a long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. *J Am Soc Nephrol* 1996; **7**: 1131-1138 [PMID: 8866403 DOI: [10.1681/ASN.V781131](https://doi.org/10.1681/ASN.V781131)]
- 80 **Blanca L**, Jiménez T, Cabello M, Sola E, Gutierrez C, Burgos D, Lopez V, Hernandez D. Cardiovascular risk in recipients with kidney transplants from expanded criteria donors. *Transplant Proc* 2012; **44**: 2579-2581 [PMID: 23146460 DOI: [10.1016/j.transproceed.2012.09.086](https://doi.org/10.1016/j.transproceed.2012.09.086)]
- 81 **Joy MS**, Hogan SL, Thompson BD, Finn WF, Nickleleit V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. *Nephrol Dial Transplant* 2007; **22**: 1963-1968 [PMID: 17395652 DOI: [10.1093/ndt/gfm133](https://doi.org/10.1093/ndt/gfm133)]
- 82 **Hauser IA**, Kruck S, Gauer S, Nies AT, Winter S, Bedke J, Geiger H, Hoefeld H, Kleemann J, Asbe-Vollkopf A, Engel J, Burk O, Schwab M, Schaeffeler E. Human pregnane X receptor genotype of the donor but not of the recipient is a risk factor for delayed graft function after renal transplantation. *Clin Pharmacol Ther* 2012; **91**: 905-916 [PMID: 22453193 DOI: [10.1038/clpt.2011.346](https://doi.org/10.1038/clpt.2011.346)]
- 83 **Reeves-Daniel AM**, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI. The APOL1 gene and allograft survival after kidney transplantation. *Am J Transplant* 2011; **11**: 1025-1030 [PMID: 21486385 DOI: [10.1111/j.1600-6143.2011.03513.x](https://doi.org/10.1111/j.1600-6143.2011.03513.x)]
- 84 **Tantisattamo E**, Molnar MZ, Ho BT, Reddy UG, Dafoe DC, Ichii H, Ferrey AJ, Hanna RM, Kalantar-Zadeh K, Amin A. Approach and Management of Hypertension After Kidney Transplantation. *Front Med (Lausanne)* 2020; **7**: 229 [PMID: 32613001 DOI: [10.3389/fmed.2020.00229](https://doi.org/10.3389/fmed.2020.00229)]
- 85 **Korogiannou M**, Xagas E, Marinaki S, Sarafidis P, Boletis JN. Arterial Stiffness in Patients With Renal Transplantation;

- Associations With Co-morbid Conditions, Evolution, and Prognostic Importance for Cardiovascular and Renal Outcomes. *Front Cardiovasc Med* 2019; **6**: 67 [PMID: 31179288 DOI: 10.3389/fcvm.2019.00067]
- 86 **Bruno S**, Remuzzi G, Ruggerenti P. Transplant renal artery stenosis. *J Am Soc Nephrol* 2004; **15**: 134-141 [PMID: 14694165 DOI: 10.1097/01.asn.0000099379.61001.f8]
 - 87 **Rengel M**, Gomes-Da-Silva G, Incháustegui L, Lampreave JL, Robledo R, Echenagusia A, Vallejo JL, Valderrábano F. Renal artery stenosis after kidney transplantation: diagnostic and therapeutic approach. *Kidney Int Suppl* 1998; **68**: S99-106 [PMID: 9839292 DOI: 10.1038/sj.ki.4490573]
 - 88 **Chen W**, Kayler LK, Zand MS, Muttana R, Chernyak V, DeBoccardo GO. Transplant renal artery stenosis: clinical manifestations, diagnosis and therapy. *Clin Kidney J* 2015; **8**: 71-78 [PMID: 25713713 DOI: 10.1093/ckj/sfu132]
 - 89 **Willicombe M**, Sandhu B, Brookes P, Gedroyc W, Hakim N, Hamady M, Hill P, McLean AG, Moser S, Papalois V, Tait P, Wilcock M, Taube D. Postanastomotic transplant renal artery stenosis: association with de novo class II donor-specific antibodies. *Am J Transplant* 2014; **14**: 133-143 [PMID: 24354873 DOI: 10.1111/ajt.12531]
 - 90 **Pouria S**, State OI, Wong W, Hendry BM. CMV infection is associated with transplant renal artery stenosis. *QJM* 1998; **91**: 185-189 [PMID: 9604070 DOI: 10.1093/qjmed/91.3.185]
 - 91 **Halimi JM**, Al-Najjar A, Buchler M, Birmelé B, Tranquart F, Alison D, Lebranchu Y. Transplant renal artery stenosis: potential role of ischemia/reperfusion injury and long-term outcome following angioplasty. *J Urol* 1999; **161**: 28-32 [PMID: 10037360 DOI: 10.1016/s0022-5347(01)62051-2]
 - 92 **Ngo AT**, Markar SR, De Lijster MS, Duncan N, Taube D, Hamady MS. A Systematic Review of Outcomes Following Percutaneous Transluminal Angioplasty and Stenting in the Treatment of Transplant Renal Artery Stenosis. *Cardiovasc Intervent Radiol* 2015; **38**: 1573-1588 [PMID: 26088719 DOI: 10.1007/s00270-015-1134-z]
 - 93 **Mangray M**, Vella JP. Hypertension after kidney transplant. *Am J Kidney Dis* 2011; **57**: 331-341 [PMID: 21251543 DOI: 10.1053/j.ajkd.2010.10.048]
 - 94 **Weir MR**, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, Mehrotra A, Mitsnefes MM, Sica DA, Taler SJ. Assessment and management of hypertension in transplant patients. *J Am Soc Nephrol* 2015; **26**: 1248-1260 [PMID: 25653099 DOI: 10.1681/ASN.2014080834]
 - 95 **Dragun D**, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. *N Engl J Med* 2005; **352**: 558-569 [PMID: 15703421 DOI: 10.1056/NEJMoa035717]
 - 96 **Kuningas K**, Driscoll J, Mair R, Smith H, Dutton M, Day E, Sharif AA. Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients: A Randomized Controlled Trial. *Transplantation* 2020; **104**: 1491-1499 [PMID: 31568390 DOI: 10.1097/TP.0000000000002969]
 - 97 **Unger T**, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension global hypertension practice guidelines. *J Hypertens* 2020; **38**: 982-1004 [PMID: 32371787 DOI: 10.1097/HJH.0000000000002453]
 - 98 **Sarafidis PA**, Ruilope LM. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? *Kidney Int* 2014; **85**: 536-546 [PMID: 24048382 DOI: 10.1038/ki.2013.355]
 - 99 **Pisano A**, Bolognani D, Mallamaci F, D'Arrigo G, Halimi JM, Persu A, Wuerzner G, Sarafidis P, Watschinger B, Burnier M, Zoccali C. Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. *Nephrol Dial Transplant* 2020; **35**: 878-887 [PMID: 31143926 DOI: 10.1093/ndt/gfz092]
 - 100 **Cross NB**, Webster AC, Masson P, O'Connell PJ, Craig JC. Antihypertensive treatment for kidney transplant recipients. *Cochrane Database Syst Rev* 2009; CD003598 [PMID: 19588343 DOI: 10.1002/14651858.CD003598.pub2]
 - 101 **van Riemsdijk IC**, Mulder PG, de Fijter JW, Bruijn JA, van Hooff JP, Hoitsma AJ, Tegzess AM, Weimar W. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. *Transplantation* 2000; **70**: 122-126 [PMID: 10919587]
 - 102 **van den Dorpel MA**, Zietse R, Ijzermans JN, Weimar W. Prophylactic isradipine treatment after kidney transplantation: a prospective double-blind placebo-controlled randomized trial. *Transpl Int* 1994; **7** Suppl 1: S270-S274 [PMID: 11271223 DOI: 10.1111/j.1432-2277.1994.tb01365.x]
 - 103 **Harper SJ**, Moorhouse J, Abrams K, Jurewicz A, Nicholson M, Horsburgh T, Harris K, Combe C, Bell PR, Walls J, Donnelly PK, Veitch PS, Feehally J. The beneficial effects of oral nifedipine on cyclosporin-treated renal transplant recipients--a randomised prospective study. *Transpl Int* 1996; **9**: 115-125 [PMID: 8639252 DOI: 10.1007/BF00336388]
 - 104 **Heinze G**, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. *J Am Soc Nephrol* 2006; **17**: 889-899 [PMID: 16481415 DOI: 10.1681/ASN.2005090955]
 - 105 **Opelz G**, Zeier M, Laux G, Morath C, Döhler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. *J Am Soc Nephrol* 2006; **17**: 3257-3262 [PMID: 17035607 DOI: 10.1681/ASN.2006050543]
 - 106 **Midtvedt K**, Hartmann A, Foss A, Fauchald P, Nordal KP, Rootwelt K, Holdaas H. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. *Transplantation* 2001; **72**: 1787-1792 [PMID: 11740389 DOI: 10.1097/00007890-200112150-00013]
 - 107 **Hernández E**, Morales JM, Andrés A, Ortuño B, Praga M, Alcazar JM, Fernández G, Rodicio JL. Usefulness and safety of treatment with captopril in posttransplant erythrocytosis. *Transplant Proc* 1995; **27**: 2239-2241 [PMID: 7652789]
 - 108 **Sennesaal J**, Lamote J, Violet I, Tasse S, Verbeelen D. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. *Hypertension* 1995; **26**: 436-444 [PMID: 7649579 DOI: 10.1161/01.hyp.26.3.436]
 - 109 **van der Schaaf MR**, Hené RJ, Floor M, Blankenstijn PJ, Koomans HA. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? *Hypertension* 1995; **25**: 77-81 [PMID: 7843758 DOI: 10.1161/01.hyp.25.1.77]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

